A population pharmacokinetic model is beneficial in quantifying hair concentrations of ritonavir-boosted atazanavir: a study of HIV-infected Zimbabwean adolescents
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2050-6511
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
A population pharmacokinetic model is beneficial in quantifying hair concentrations of ritonavir-boosted atazanavir: a study of HIV-infected Zimbabwean adolescents ; volume:21 ; number:1 ; day:3 ; month:8 ; year:2020 ; pages:1-9 ; date:12.2020
BMC pharmacology & toxicology ; 21, Heft 1 (3.8.2020), 1-9, 12.2020
- Creator
-
Ngara, Bernard
Zvada, Simbarashe
Chawana, Tariro Dianah
Stray-Pedersen, Babill
Nhachi, Charles Fungai Brian
Rusakaniko, Simbarashe
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40360-020-00437-y
- URN
-
urn:nbn:de:101:1-2020092822200914943890
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:56 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ngara, Bernard
- Zvada, Simbarashe
- Chawana, Tariro Dianah
- Stray-Pedersen, Babill
- Nhachi, Charles Fungai Brian
- Rusakaniko, Simbarashe
- SpringerLink (Online service)
Other Objects (12)
Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients
Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastin in HIV-infected patients with Hodgkin lymphoma
Efficacy and safety of ritonavir-boosted fosamprenavir (FPV/r) in HIV-infected patients: 48-week results from an observational study
Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment
Long-term efficacy and safety of low-dose ritonavir-boosted atazanavir (ATV/r) 200/100 mg in HIV-infected Thai patients
Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study
Wirksamkeit und Verträglichkeit von Lopinavir, Ritonavir, einem boosted Proteaseinhibitor, in der antiretroviralen Therapie
An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir
Herb-drug interaction between Echinacea purpurea and darunavir/ritonavir in HIV-infected patients
Lipometabolic side-effects of three ritonavir-boosted double protease inhibitor regimens without reverse transcriptase inhibitors
Correction to: Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling
Population pharmacokinetic/pharmacodynamic analysis of lopinavir and ritonavir in subjects receiving the tablet formulation
Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients
Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastin in HIV-infected patients with Hodgkin lymphoma
Efficacy and safety of ritonavir-boosted fosamprenavir (FPV/r) in HIV-infected patients: 48-week results from an observational study
Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment
Long-term efficacy and safety of low-dose ritonavir-boosted atazanavir (ATV/r) 200/100 mg in HIV-infected Thai patients
Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study
Wirksamkeit und Verträglichkeit von Lopinavir, Ritonavir, einem boosted Proteaseinhibitor, in der antiretroviralen Therapie
An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir
Herb-drug interaction between Echinacea purpurea and darunavir/ritonavir in HIV-infected patients
Lipometabolic side-effects of three ritonavir-boosted double protease inhibitor regimens without reverse transcriptase inhibitors
Correction to: Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling
Population pharmacokinetic/pharmacodynamic analysis of lopinavir and ritonavir in subjects receiving the tablet formulation
Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients
Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastin in HIV-infected patients with Hodgkin lymphoma
Efficacy and safety of ritonavir-boosted fosamprenavir (FPV/r) in HIV-infected patients: 48-week results from an observational study
Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment
Long-term efficacy and safety of low-dose ritonavir-boosted atazanavir (ATV/r) 200/100 mg in HIV-infected Thai patients
Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study
Wirksamkeit und Verträglichkeit von Lopinavir, Ritonavir, einem boosted Proteaseinhibitor, in der antiretroviralen Therapie
An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir
Herb-drug interaction between Echinacea purpurea and darunavir/ritonavir in HIV-infected patients
Lipometabolic side-effects of three ritonavir-boosted double protease inhibitor regimens without reverse transcriptase inhibitors
Correction to: Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling